Members Only Content

Subscribe to get full access

Free Preview

Moderna has been a stock market darling but its share price has fallen by around half from its 52-week high. Now, problems are piling up for the company which has slashed its revenue projections largely based on lower-than-expected sales of its COVID-19 vaccine. The company also faces a lawsuit from the U.S. National Institutes of Health over ownership of that vaccine. Those problems, along with concerns about the future when the pandemic ends,have been a drag on the company’s stock which could fall further. Maxx Chatsko joins “7investing Now” to break down what’s happening and share what might happen next.

related news & insights

  • February 14, 2025||0 min||||

    Novo Nordisk Deep Dive: February 2025

    Novo Nordisk Recommendation Feb 2025

  • February 1, 2025||4.9 min||||

    X’s Favorite Small-Cap Growth Stocks

    We did something special this month. In addition to sharing our 7investing Community's favorite new ideas, we also asked an [...]

  • January 30, 2025||10 min||||

    “Staying Focused”: Here’s Why STAAR Surgical Has 41% Upside

    See my previous Discounted Cash Flows for Coupang , Rocket Lab , Tesla, and The Trade Desk. Some investors describe [...]